24/7 Market News Snapshot 05 May, 2025 – Alterity Therapeutics Limited American Depositary Shares (NASDAQ:ATHE)

May 5, 2025

DENVER, Colo., 05 May, 2025 (www.247marketnews.com) – (NASDAQ:ATHE) are discussed in this article.
Alterity Therapeutics Limited (ATHE) has experienced a remarkable surge in its stock price, opening at $3.70 and currently trading at approximately $3.95, reflecting an increase of around 14.97% from the previous session’s close at $3.44. This rise has been accompanied by a substantial trading volume of 512.77K shares, indicating robust investor interest and a prevailing bullish sentiment. Market analysts suggest that if ATHE maintains its position above the $3.90 threshold, further upside potential could be anticipated, while support is projected around the $3.70 level. These developments signal promising activity, urging stakeholders to closely monitor the stock for potential trends.

In addition to its stock performance, Alterity Therapeutics has recently achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation for its lead candidate, ATH434, intended for the treatment of Multiple System Atrophy (MSA), a rare and debilitating neurodegenerative disease lacking approved therapeutic options. David Stamler, M.D., Chief Executive Officer, emphasized the importance of this designation, noting that it enables accelerated dialogue with the FDA, thereby enhancing the timeline for development and potential marketing approval.

The Fast Track designation follows encouraging data from Alterity’s Phase 2 clinical trial, where ATH434 exhibited strong clinical efficacy, demonstrating its ability to potentially modify disease progression. As an oral iron chaperone, ATH434 targets the aggregation of harmful proteins implicated in neurodegeneration, showing promise in preclinical studies by restoring iron balance and reducing α-synuclein pathology.

This designation not only facilitates more frequent interactions with the FDA but also opens the door to Accelerated Approval and rolling review procedures, positioning Alterity favorably to expedite access to this much-needed therapy for patients suffering from MSA. The company remains committed to delivering transformative treatments for neurodegenerative diseases, ensuring innovative therapeutic options for those affected.

Related news for (ATHE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.